301580.SZ
爱迪特
SZSE · Healthcare · C 制造业 · CN
CNY 48.96
−4.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.0B | 888.2M | 780.4M | 602.7M |
| Cost of Revenue | 503.7M | 491.0M | 418.0M | 396.9M | 329.1M |
| Gross Profit | 583.2M | 543.8M | 470.2M | 383.4M | 273.6M |
| Operating Expenses | |||||
| R&D Expense | 81.2M | 73.6M | 47.4M | 40.1M | 27.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 76.8M | 78.3M | 70.4M | 59.1M | 48.5M |
| Selling & Marketing Expense | 205.7M | 200.7M | 180.8M | 129.9M | 89.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 379.5M | 355.1M | 300.7M | 225.0M | 149.7M |
| Cost and Expenses | 883.2M | 846.1M | 718.7M | 622.0M | 478.8M |
| Operating Income (EBIT) | 224.2M | 215.7M | 174.1M | 171.2M | 133.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 224.4M | 216.2M | 171.4M | 170.6M | 132.0M |
| Income Tax Expense | 19.9M | 19.9M | 21.9M | 23.3M | 15.7M |
| Bottom Line | |||||
| Net Income | 203.2M | 196.2M | 150.5M | 147.0M | 115.8M |
| Earnings from Cont. Ops | 204.5M | 196.3M | 149.5M | 147.2M | 116.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 203.2M | 196.2M | 150.5M | 147.0M | 115.8M |
| Per Share | |||||
| Basic EPS | CN¥1.90 | CN¥1.84 | CN¥1.55 | CN¥2.57 | CN¥2.03 |
| Diluted EPS | CN¥1.90 | CN¥1.84 | CN¥1.55 | CN¥2.57 | CN¥2.03 |
| Revenue Per Share | CN¥10.20 | CN¥9.70 | CN¥9.15 | CN¥13.65 | CN¥10.57 |
| Shares | |||||
| Basic Shares Outstanding | 106.6M | 106.6M | 97.1M | 57.2M | 57.0M |
| Diluted Shares Outstanding | 106.6M | 106.6M | 97.1M | 57.2M | 57.0M |
| Profitability Metrics | |||||
| EBITDA | — | 253.3M | 200.5M | 185.8M | 143.3M |
| D&A | — | 37.7M | 26.4M | 14.6M | 9.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026